James E. Flynn and Deerfield Entities Reduce Stake in BiomX Inc. Below 5% Threshold

On June 16, 2026, James E. Flynn and several Deerfield-related entities (including Deerfield Private Design Fund V, L.P. and Deerfield Healthcare Innovations Fund II, L.P.) filed Amendment No. 7 to their Schedule 13D for BiomX Inc. (PHGE). The filing reveals a significant reduction in their collective position, with James E. Flynn's beneficial ownership dropping from 8.09% to 4.7%. As of June 12, 2026, the reporting persons ceased to be beneficial owners of more than five percent of the company's outstanding common stock. The reduction was driven by a series of open-market sales between June 12 and June 16, 2026. Specifically, Deerfield Private Design Fund V and Deerfield Healthcare Innovations Fund II each sold approximately 154,939 shares during this period at weighted average prices ranging from $0.5538 to $0.5772 per share. Following these transactions, the reporting group holds a total of 533,370 shares, which includes common stock, exercisable warrants (subject to a 9.99% beneficial ownership limitation), and options held for the benefit of Deerfield Management.